Lactiplantibacillus plantarum P101 Mitigates Alcoholic Hepatic Steatosis via AMPK Pathway Activation

Study Background and Research Question

Alcoholic liver disease (ALD) remains a significant global health burden, accounting for approximately 3 million deaths worldwide as of 2016. The earliest and most reversible phase of ALD is alcoholic fatty liver disease (AFLD), affecting over 90% of individuals with chronic alcohol intake. AFLD is characterized by hepatic triglyceride (TG) overaccumulation, resulting from impaired fatty acid oxidation and upregulated lipogenesis. Given AFLD’s reversibility, early interventions targeting hepatic lipid metabolism are of great interest.

Recent research has focused on the role of 5′-adenosine monophosphate-activated protein kinase (AMPK), a key regulator of energy homeostasis, which restricts anabolic and promotes catabolic pathways in the liver. Downregulation of AMPK by alcohol consumption disturbs lipid metabolism, leading to steatosis. Probiotics, especially Lactobacillus species, have emerged as potential nutritional interventions for metabolic liver diseases due to their roles in modulating oxidative stress, inflammation, and gut-liver axis signaling. However, the mechanistic underpinnings of probiotic action on hepatic lipid metabolism, particularly via the AMPK signaling pathway, remain incompletely defined.

The reference study sought to determine whether Lactiplantibacillus plantarum P101 (LP.P101) could alleviate alcohol-induced hepatic lipid accumulation in mice and to dissect the involvement of AMPK activation, gut microbiota shifts, and serum metabolite changes in this process (reference study).

Key Innovation from the Reference Study

This work distinguishes itself by directly interrogating the causative role of AMPK signaling in probiotic-mediated protection against alcohol-induced steatosis. Using the selective AMPK inhibitor dorsomorphin, the investigators provided strong evidence that the hepatoprotective effects of LP.P101 are AMPK-dependent. Furthermore, they integrated gut microbiota and metabolomic analyses, revealing that LP.P101’s effects extend beyond the liver and are mediated by systemic interactions involving microbial metabolites.

By mapping correlations between specific bacterial taxa, serum metabolites, and hepatic lipid and AMPK activity metrics, the study uncovers a multi-level mechanistic framework for microbiota-driven metabolic regulation in AFLD.

Methods and Experimental Design Insights

The experimental design combined a widely used mouse model of AFLD with targeted probiotic intervention and pharmacological pathway inhibition:

• Animal Model: Mice received a 10-day ethanol feeding protocol, including a final binge ethanol dose to induce hepatic steatosis.
• Probiotic Intervention: Daily oral gavage of LP.P101 at 10⁸ CFU/mL.
• AMPK Inhibition: The AMPK inhibitor dorsomorphin was administered to a subgroup to test pathway dependency.
• Endpoints: Hepatic histology (lipid droplet quantification), serum biomarkers (ALT, TG), AMPK phosphorylation status, hepatic gene expression, gut microbiota profiling (16S rRNA sequencing), and untargeted metabolomics.

Critically, the use of dorsomorphin to block AMPK activation enabled causal inference regarding the necessity of this pathway in mediating LP.P101’s benefit.

Protocol Parameters

• Mouse AFLD induction: 10-day liquid ethanol diet followed by single binge dose.
• Probiotic dosing: 10⁸ CFU/mL LP.P101 by oral gavage daily throughout ethanol exposure.
• AMPK inhibitor use: Dorsomorphin administered at a dose and schedule sufficient to block hepatic AMPK activation (exact values not specified in the summary; consult full paper or product information for dosing guidance).
• Metabolic and histological endpoints: Hepatic TG, ALT measurement, Oil Red O staining for lipid droplets, and Western blot for AMPK/p-AMPK.

Core Findings and Why They Matter

LP.P101 supplementation substantially reduced hepatic lipid accumulation and improved serum indicators of liver injury in ethanol-fed mice. Mechanistically, the probiotic restored AMPK phosphorylation at Thr172, which was suppressed by alcohol exposure. Inhibition of AMPK with dorsomorphin abrogated these benefits, confirming pathway specificity.

Gut microbiota analysis revealed that LP.P101 decreased the relative abundance of Firmicutes and increased Bacteroidetes, a community shift previously linked to improved metabolic outcomes. Notably, the presence of Parabacteroides merdae correlated negatively with hepatic lipid accumulation, while unclassified Negativibacillus was associated with lower AMPK activation.

Serum metabolomics identified stercobilinogen as a candidate biomarker, positively correlated with AMPK activation and inversely with hepatic steatosis. These findings support a model in which LP.P101 modulates the gut-liver axis, influencing hepatic metabolism via both direct AMPK activation and altered microbial metabolite profiles (reference study).

Comparison with Existing Internal Articles

These results complement and extend previous insights, such as those discussed in "AMPK Pathway Modulation in Alcoholic Liver Disease: Insights from L. plantarum P101". Both sources highlight the AMPK pathway as a pivotal regulatory node in hepatic lipid handling under probiotic intervention. However, the current study uniquely leverages an AMPK inhibitor to definitively attribute the effects of LP.P101 to this pathway, a distinction not directly addressed by earlier summaries.

Further, resources such as "Dorsomorphin 2HCl: AMPK Inhibitor Workflows in Metabolic Research" provide practical guidance for implementing AMPK and BMP pathway inhibition in preclinical studies. The present work exemplifies such workflows, confirming the translational value of pathway-specific pharmacological tools like dorsomorphin in dissecting metabolic disease mechanisms.

Limitations and Transferability

Some limitations should be acknowledged. The study was conducted in a short-term murine model, which may not fully recapitulate the chronic progression and complexity of human ALD. The precise dosing and pharmacokinetics of dorsomorphin were not detailed in the summary, necessitating careful optimization for future work. Furthermore, while the integration of multi-omic data is a strength, causal relationships between specific gut taxa, metabolites, and hepatic endpoints require further validation, potentially via gnotobiotic or metabolite supplementation studies.

Nevertheless, the demonstration that probiotic-driven AMPK activation is necessary for reversing hepatic steatosis provides a robust framework for further translational research. The findings are directly transferable to preclinical models of metabolic liver disease and lay groundwork for exploring similar mechanisms in other contexts of hepatic metabolic dysfunction.

Research Support Resources

For researchers aiming to replicate or extend these findings, selective pharmacological pathway inhibition is crucial. Dorsomorphin 2HCl (SKU B1372) is a widely used AMPK inhibitor and BMP signaling pathway modulator suitable for in vitro and in vivo workflows involving hepatic lipid metabolism, osteogenic differentiation, and iron homeostasis studies. Detailed handling and solubility protocols are available in the product dossier. Employing this compound enables precise dissection of AMPK-dependent mechanisms in metabolic research.